VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+25.81%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$241M
AUM Growth
+$50.3M
(+26%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
4.82%
Top 10 Holdings %
Top 10 Hldgs %
9.37%
Holding
372
New
47
Increased
146
Reduced
160
Closed
17
Top Buys
| 1 |
Brookfield Renewable
BEPC
|
$1.83M |
| 2 |
Western Midstream Partners
WES
|
$1.11M |
| 3 |
Delek US
DK
|
$829K |
| 4 |
Viper Energy
VNOM
|
$789K |
| 5 |
Oneok
OKE
|
$751K |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$1.61M |
| 2 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$1.13M |
| 3 |
AIV
Aimco
AIV
|
$1.11M |
| 4 |
Telefônica Brasil
VIV
|
$1.01M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$988K |
Sector Composition
| 1 | Healthcare | 29.53% |
| 2 | Real Estate | 18.96% |
| 3 | Energy | 16.61% |
| 4 | Materials | 11.31% |
| 5 | Utilities | 7.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Kezar Life Sciences
KZR
$29.8M
| $278K | 0.12% |
5,335
-1,034
| -16% | -$53.9K |
|
252
Prothena Corp
PRTA
$460M
| $278K | 0.12% |
23,175
-8,700
| -27% | -$104K |
|
253
Q32 Bio
QTTB
$20.4M
| $278K | 0.12% |
1,369
+216
| +19% | +$43.9K |
|
254
Ardelyx
ARDX
$1.57B
| $277K | 0.12% |
42,880
-3,895
| -8% | -$25.2K |
|
255
Compugen
CGEN
$134M
| $277K | 0.12% |
22,834
+685
| +3% | +$8.31K |
|
256
Legend Biotech
LEGN
$6.66B
| $277K | 0.12% |
+9,834
| New | +$277K |
|
257
Oaktree Specialty Lending
OCSL
$1.23B
| $277K | 0.12% |
16,555
-3,169
| -16% | -$53K |
|
258
Verastem
VSTM
$663M
| $277K | 0.12% |
10,830
-3,763
| -26% | -$96.2K |
|
|
OYST
259
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $277K | 0.12% |
14,729
+4,017
| +38% | +$75.5K |
|
260
ADC Therapeutics
ADCT
$398M
| $276K | 0.11% |
+8,616
| New | +$276K |
|
261
Black Diamond Therapeutics
BDTX
$167M
| $276K | 0.11% |
8,603
-317
| -4% | -$10.2K |
|
|
MRTX
262
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $276K | 0.11% |
1,256
-1,764
| -58% | -$388K |
|
|
KDMN
263
DELISTED
Kadmon Holdings, Inc.
KDMN
| $276K | 0.11% |
66,594
-861
| -1% | -$3.57K |
|
|
SYRS
264
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $275K | 0.11% |
2,532
-952
| -27% | -$103K |
|
|
MRNS
265
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $275K | 0.11% |
22,503
-9,734
| -30% | -$119K |
|
266
89bio
ETNB
$1.32B
| $272K | 0.11% |
+11,154
| New | +$272K |
|
267
Iovance Biotherapeutics
IOVA
$901M
| $272K | 0.11% |
5,870
-4,580
| -44% | -$212K |
|
268
Madrigal Pharmaceuticals
MDGL
$9.65B
| $272K | 0.11% |
2,444
-435
| -15% | -$48.4K |
|
269
Quince Therapeutics
QNCX
$86.5M
| $272K | 0.11% |
9,804
+2,958
| +43% | +$82.1K |
|
|
GMDA
270
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $272K | 0.11% |
+32,455
| New | +$272K |
|
271
Cue Biopharma
CUE
$59.9M
| $271K | 0.11% |
21,660
+9,599
| +80% | +$120K |
|
272
Zymeworks
ZYME
$1.14B
| $271K | 0.11% |
5,726
-3,295
| -37% | -$156K |
|
|
GTHX
273
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $271K | 0.11% |
15,055
-1,658
| -10% | -$29.8K |
|
274
Geron
GERN
$893M
| $270K | 0.11% |
169,547
-20,716
| -11% | -$33K |
|
275
Gossamer Bio
GOSS
$668M
| $270K | 0.11% |
27,963
+2,834
| +11% | +$27.4K |
|